Back to Newsroom

Scioderm, Inc. to Present Data from Phase 2b Study of ZorblisaTM (SD-101) at the debra International Congress

Durham, N.C. (September 9, 2014) — Scioderm, Inc., today announced Dr. Robert Ryan, president and chief executive officer, will present at the Dystrophic Epidermolysis Bullosa Research Association (debra®) International Congress, Saturday, September 20, 2014 at 12:40 pm CEST at the Espaces CAP – 15 1/13 Quai de Grenelle in Paris, France. Dr. Ryan will provide an update of the development program for their lead investigational therapy, ZorblisaTM (SD-101), including data from their recently completed Phase 2b study (SD-003). Zorblisa is in late stage clinical development for the treatment of skin blistering and lesions associated with inherited Epidermolysis Bullosa (EB), a pediatric orphan disease.

Click here to read more